Predictors and benefits of lipid-lowering therapy initiation after an atherosclerotic cardiovascular event: a retrospective cohort study

Manuela Casula^1,2*Stefano Scotti^1,2Federica Galimberti²Giacomo Matteo Bruno^3,4Giorgio Lorenzo Colombo^3,4Asiiat Alieva⁵Sining Xie¹Alberico Luigi Catapano^1,2Elena Olmastroni^1,2

• ¹Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Lombardy, Italy
• ²IRCCS MultiMedica, Sesto S. Giovanni (MI), Italy, Sesto San Giovanni (MI), Italy
• ³Center of Research, S.A.V.E. Studi - Health Economics and Outcomes Research, Milan, Italy, Pavia, Italy
• ⁴Department of Drug Sciences, University of Pavia, Italy, Pavia, Italy
• ⁵Research laboratory of lipid disorders and atherosclerosis, Almazov National Medical Research Centre, Saint Petersburg, Russia, Saint Petersburg, Russia

Background Guidelines recommend lipid-lowering therapy (LLT) after an atherosclerotic cardiovascular disease (ASCVD) event. This study investigated real-world LLT initiation rate and its effect on total mortality in the Lombardy region.Methods Individuals aged ≥40 with an ASCVD event between January and September 2022 were identified from Lombardy's administrative data. The prevalence of LLT initiation within 3 months was estimated, and factors influencing treatment initiation were evaluated using multivariate logistic regression (odds ratios [OR] and 95% confidence intervals [95% CI]). One-year post-event mortality was analyzed. Results Among 16,025 patients 41.14% did not receive a LLT after an ASCVD event. Treatment initiation was more likely in subjects hospitalized for a cardiovascular event (OR 2.22, 95%CI 2.07-2.38, vs cerebrovascular event), in patients aged 51-60 years (OR 1.30, 95%CI 1.16-1.46), and in patients previously treated with antidiabetic (OR 1.42, 95%CI 1.25-1.62), antihypertensive (OR 1.96, 95%CI 1.80-2.13), and thyroid hormone replacement medications (OR 1.34,. Conversely, older age (71-80 years: OR 0.79, 95%CI 0.71-0.87; >80 years: OR 0.47, 95%CI 0.42-0.52), female sex (OR 0.73, 95%CI 0.68-0.79), previous exposure to antithrombotic medications (OR 0.65, 95%CI 0.59-0.72), and polypharmacy (OR 0.90, 95%CI 0.81-0.99 for 5-9 medications, OR 0.61, 95%CI 0.52-0.72 for ≥10 medications) reduced the likelihood of treatment. Mortality at 1 year was 3.07% in treated versus 11.66% in untreated patients (p-value <0.001).This study underscores a suboptimal LLT initiation rate in post-ASCVD patients. Initiating LLT is associated with significantly reduced 1-year total mortality, highlighting the need to optimize secondary prevention strategies.